Jennifer Taylor-Cousar
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cystic Fibrosis | 112 | 2025 | 1049 | 22.160 |
Why?
| Cystic Fibrosis Transmembrane Conductance Regulator | 67 | 2025 | 312 | 14.270 |
Why?
| Quinolones | 27 | 2025 | 126 | 8.760 |
Why?
| Aminophenols | 41 | 2025 | 144 | 8.480 |
Why?
| Benzodioxoles | 27 | 2025 | 105 | 5.750 |
Why?
| Chloride Channel Agonists | 26 | 2025 | 77 | 4.950 |
Why?
| Sinusitis | 11 | 2024 | 203 | 3.850 |
Why?
| Indoles | 16 | 2025 | 372 | 2.990 |
Why?
| Rhinitis | 9 | 2024 | 148 | 2.960 |
Why?
| Olfaction Disorders | 7 | 2024 | 60 | 2.180 |
Why?
| Aminopyridines | 6 | 2025 | 95 | 2.150 |
Why?
| Mutation | 34 | 2024 | 3696 | 2.020 |
Why?
| Pyrazoles | 14 | 2025 | 404 | 1.940 |
Why?
| Membrane Transport Modulators | 3 | 2020 | 7 | 1.900 |
Why?
| Pongo pygmaeus | 3 | 2024 | 7 | 1.880 |
Why?
| Drug Combinations | 21 | 2025 | 324 | 1.830 |
Why?
| Pregnancy Complications | 5 | 2024 | 491 | 1.760 |
Why?
| Pyrrolidines | 10 | 2025 | 67 | 1.700 |
Why?
| Ape Diseases | 3 | 2024 | 7 | 1.620 |
Why?
| Pyridines | 12 | 2025 | 474 | 1.550 |
Why?
| Reproductive Health | 9 | 2024 | 86 | 1.430 |
Why?
| Pregnancy Outcome | 6 | 2024 | 390 | 1.350 |
Why?
| Azithromycin | 7 | 2021 | 92 | 1.350 |
Why?
| Humans | 121 | 2025 | 128499 | 1.250 |
Why?
| Parents | 5 | 2024 | 1307 | 1.160 |
Why?
| Quality of Life | 16 | 2024 | 2688 | 1.160 |
Why?
| Respiratory System Agents | 2 | 2020 | 22 | 1.150 |
Why?
| Reproductive Techniques, Assisted | 3 | 2025 | 34 | 1.130 |
Why?
| Pregnancy | 19 | 2025 | 6373 | 1.100 |
Why?
| Adult | 58 | 2025 | 35302 | 1.070 |
Why?
| Paranasal Sinuses | 5 | 2024 | 74 | 1.010 |
Why?
| Female | 68 | 2025 | 68268 | 0.940 |
Why?
| Sexual Health | 5 | 2024 | 54 | 0.920 |
Why?
| Pseudomonas Infections | 9 | 2024 | 218 | 0.920 |
Why?
| Anti-Bacterial Agents | 12 | 2024 | 1705 | 0.910 |
Why?
| Drug Approval | 3 | 2024 | 86 | 0.900 |
Why?
| Pregnancy Rate | 3 | 2021 | 60 | 0.890 |
Why?
| Pongo | 2 | 2021 | 6 | 0.870 |
Why?
| Chronic Disease | 13 | 2024 | 1692 | 0.840 |
Why?
| Lung Transplantation | 1 | 2024 | 278 | 0.750 |
Why?
| Diabetes Mellitus | 2 | 2022 | 996 | 0.730 |
Why?
| Prospective Studies | 15 | 2024 | 7069 | 0.720 |
Why?
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 18 | 0.710 |
Why?
| Sweat | 9 | 2025 | 46 | 0.670 |
Why?
| Male | 53 | 2025 | 63045 | 0.670 |
Why?
| Lung | 9 | 2023 | 3748 | 0.670 |
Why?
| Compassionate Use Trials | 1 | 2019 | 7 | 0.660 |
Why?
| Treatment Outcome | 20 | 2025 | 10162 | 0.660 |
Why?
| Drug Monitoring | 6 | 2020 | 190 | 0.660 |
Why?
| Aerosols | 1 | 2020 | 168 | 0.650 |
Why?
| Precision Medicine | 2 | 2021 | 386 | 0.640 |
Why?
| Sputum | 5 | 2022 | 301 | 0.630 |
Why?
| Fertility | 3 | 2025 | 159 | 0.630 |
Why?
| Pseudomonas aeruginosa | 9 | 2022 | 344 | 0.620 |
Why?
| Forced Expiratory Volume | 11 | 2023 | 511 | 0.570 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 252 | 0.560 |
Why?
| Breast Feeding | 2 | 2022 | 422 | 0.550 |
Why?
| Aldehyde Oxidoreductases | 1 | 2017 | 27 | 0.550 |
Why?
| Biomedical Research | 3 | 2024 | 633 | 0.530 |
Why?
| Rifampin | 1 | 2017 | 85 | 0.520 |
Why?
| Pongo abelii | 1 | 2016 | 2 | 0.520 |
Why?
| Child | 22 | 2025 | 20805 | 0.510 |
Why?
| Chlorides | 8 | 2025 | 137 | 0.500 |
Why?
| Glucose Tolerance Test | 1 | 2016 | 356 | 0.480 |
Why?
| Glucose Intolerance | 1 | 2016 | 142 | 0.480 |
Why?
| Sildenafil Citrate | 2 | 2014 | 59 | 0.480 |
Why?
| Bronchiectasis | 1 | 2016 | 108 | 0.460 |
Why?
| Surveys and Questionnaires | 10 | 2025 | 5371 | 0.460 |
Why?
| Tobramycin | 5 | 2019 | 51 | 0.460 |
Why?
| Leukocyte Elastase | 1 | 2014 | 74 | 0.460 |
Why?
| Infertility, Male | 2 | 2025 | 60 | 0.450 |
Why?
| Young Adult | 21 | 2025 | 12349 | 0.450 |
Why?
| Adolescent | 23 | 2025 | 20304 | 0.440 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2020 | 564 | 0.440 |
Why?
| Smell | 3 | 2024 | 133 | 0.430 |
Why?
| Genetic Therapy | 3 | 2023 | 292 | 0.420 |
Why?
| Double-Blind Method | 10 | 2025 | 1856 | 0.400 |
Why?
| Respiratory Function Tests | 6 | 2025 | 580 | 0.390 |
Why?
| Quinolines | 3 | 2025 | 155 | 0.390 |
Why?
| Lactation | 3 | 2022 | 170 | 0.380 |
Why?
| Contraception Behavior | 2 | 2025 | 97 | 0.380 |
Why?
| Homozygote | 4 | 2021 | 193 | 0.360 |
Why?
| Contraception | 2 | 2025 | 153 | 0.350 |
Why?
| Drug Interactions | 4 | 2020 | 361 | 0.330 |
Why?
| International Cooperation | 2 | 2020 | 173 | 0.320 |
Why?
| Hypoventilation | 1 | 2009 | 10 | 0.320 |
Why?
| Respiratory Muscles | 1 | 2009 | 32 | 0.320 |
Why?
| Genotype | 7 | 2023 | 1830 | 0.310 |
Why?
| ABO Blood-Group System | 1 | 2009 | 39 | 0.310 |
Why?
| Parenting | 2 | 2023 | 296 | 0.300 |
Why?
| Tomography, X-Ray Computed | 4 | 2022 | 2517 | 0.290 |
Why?
| Needs Assessment | 2 | 2020 | 356 | 0.280 |
Why?
| Blood Glucose | 2 | 2016 | 2092 | 0.280 |
Why?
| Clinical Trials as Topic | 2 | 2022 | 1003 | 0.260 |
Why?
| Polymorphism, Genetic | 1 | 2009 | 639 | 0.250 |
Why?
| Asthma | 3 | 2024 | 2213 | 0.250 |
Why?
| United States | 10 | 2025 | 13840 | 0.240 |
Why?
| Animals | 10 | 2024 | 34647 | 0.240 |
Why?
| Observational Studies as Topic | 2 | 2024 | 108 | 0.240 |
Why?
| Infant, Newborn | 4 | 2024 | 5740 | 0.220 |
Why?
| Alleles | 6 | 2023 | 842 | 0.220 |
Why?
| Minimal Clinically Important Difference | 1 | 2023 | 13 | 0.220 |
Why?
| Fertility Preservation | 1 | 2024 | 53 | 0.220 |
Why?
| Middle Aged | 17 | 2025 | 30923 | 0.220 |
Why?
| Orphan Drug Production | 1 | 2023 | 5 | 0.220 |
Why?
| Patient Selection | 2 | 2019 | 661 | 0.220 |
Why?
| Pregnancy, Unplanned | 2 | 2023 | 45 | 0.210 |
Why?
| C-Reactive Protein | 2 | 2018 | 398 | 0.210 |
Why?
| Abortion, Spontaneous | 1 | 2023 | 99 | 0.210 |
Why?
| Respiratory Tract Diseases | 1 | 2024 | 148 | 0.200 |
Why?
| Biomarkers | 5 | 2024 | 3893 | 0.200 |
Why?
| Ion Transport | 2 | 2021 | 57 | 0.200 |
Why?
| Body Height | 1 | 2023 | 193 | 0.200 |
Why?
| Neonatal Screening | 1 | 2024 | 164 | 0.200 |
Why?
| Puberty | 1 | 2023 | 143 | 0.200 |
Why?
| Epoxide Hydrolases | 1 | 2021 | 11 | 0.190 |
Why?
| Azabicyclo Compounds | 1 | 2021 | 6 | 0.190 |
Why?
| Enzyme Activators | 1 | 2021 | 7 | 0.190 |
Why?
| RNA, Messenger | 3 | 2022 | 2679 | 0.190 |
Why?
| Benzoates | 1 | 2021 | 41 | 0.190 |
Why?
| Dose-Response Relationship, Drug | 2 | 2017 | 1951 | 0.190 |
Why?
| Endoscopy | 4 | 2024 | 271 | 0.180 |
Why?
| Men's Health | 1 | 2020 | 7 | 0.180 |
Why?
| Multicenter Studies as Topic | 1 | 2022 | 286 | 0.180 |
Why?
| Infertility | 1 | 2021 | 51 | 0.180 |
Why?
| Retrospective Studies | 10 | 2024 | 14472 | 0.180 |
Why?
| Disease Progression | 5 | 2020 | 2604 | 0.170 |
Why?
| Women's Rights | 1 | 2020 | 4 | 0.170 |
Why?
| Communicable Disease Control | 1 | 2020 | 73 | 0.170 |
Why?
| Virulence Factors | 2 | 2014 | 155 | 0.170 |
Why?
| Aztreonam | 2 | 2016 | 10 | 0.160 |
Why?
| Cataract | 1 | 2022 | 208 | 0.160 |
Why?
| Colistin | 1 | 2019 | 9 | 0.160 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 1276 | 0.160 |
Why?
| Follow-Up Studies | 3 | 2024 | 4874 | 0.160 |
Why?
| Neutrophils | 3 | 2016 | 1192 | 0.160 |
Why?
| Sexism | 1 | 2020 | 55 | 0.160 |
Why?
| Medication Therapy Management | 1 | 2020 | 72 | 0.160 |
Why?
| Receptors, Interleukin-8B | 1 | 2018 | 24 | 0.160 |
Why?
| Health Status | 1 | 2023 | 747 | 0.150 |
Why?
| Research Design | 1 | 2024 | 1036 | 0.150 |
Why?
| Patient Reported Outcome Measures | 1 | 2022 | 370 | 0.150 |
Why?
| Administration, Oral | 1 | 2020 | 767 | 0.150 |
Why?
| Mental Health | 1 | 2024 | 683 | 0.150 |
Why?
| Pyrimidines | 1 | 2021 | 449 | 0.140 |
Why?
| Severity of Illness Index | 5 | 2021 | 2719 | 0.140 |
Why?
| Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.140 |
Why?
| Pregnancy, High-Risk | 1 | 2017 | 15 | 0.140 |
Why?
| HEK293 Cells | 1 | 2020 | 683 | 0.140 |
Why?
| Leukocytes | 1 | 2018 | 303 | 0.140 |
Why?
| Risk Assessment | 3 | 2021 | 3232 | 0.140 |
Why?
| Longitudinal Studies | 1 | 2024 | 2710 | 0.140 |
Why?
| Respiratory Tract Infections | 1 | 2021 | 372 | 0.130 |
Why?
| Biological Availability | 1 | 2017 | 131 | 0.130 |
Why?
| Research | 1 | 2020 | 409 | 0.130 |
Why?
| Health Services Accessibility | 2 | 2024 | 901 | 0.130 |
Why?
| Biphenyl Compounds | 1 | 2017 | 60 | 0.130 |
Why?
| Prognosis | 2 | 2022 | 3780 | 0.130 |
Why?
| Risk Adjustment | 1 | 2017 | 79 | 0.130 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 222 | 0.130 |
Why?
| Recovery of Function | 1 | 2020 | 633 | 0.130 |
Why?
| Attitude of Health Personnel | 1 | 2023 | 1090 | 0.130 |
Why?
| Gene Expression Profiling | 3 | 2018 | 1689 | 0.130 |
Why?
| Albuterol | 1 | 2016 | 103 | 0.120 |
Why?
| Machine Learning | 1 | 2020 | 444 | 0.120 |
Why?
| Pilot Projects | 2 | 2020 | 1568 | 0.120 |
Why?
| Pharmacogenetics | 1 | 2017 | 172 | 0.120 |
Why?
| Child, Preschool | 3 | 2024 | 10487 | 0.120 |
Why?
| Adrenal Cortex Hormones | 1 | 2018 | 518 | 0.120 |
Why?
| Interferons | 1 | 2016 | 192 | 0.120 |
Why?
| Epithelial Cells | 2 | 2020 | 1043 | 0.120 |
Why?
| Diabetes Complications | 1 | 2016 | 223 | 0.120 |
Why?
| Cyclopropanes | 2 | 2025 | 88 | 0.120 |
Why?
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 36 | 0.120 |
Why?
| DNA Mutational Analysis | 1 | 2015 | 385 | 0.110 |
Why?
| Metalloproteases | 1 | 2014 | 43 | 0.110 |
Why?
| Bronchodilator Agents | 1 | 2016 | 243 | 0.110 |
Why?
| Staphylococcal Infections | 1 | 2019 | 392 | 0.110 |
Why?
| Genetic Predisposition to Disease | 2 | 2015 | 2269 | 0.110 |
Why?
| Body Mass Index | 2 | 2023 | 2263 | 0.110 |
Why?
| Quorum Sensing | 1 | 2014 | 77 | 0.110 |
Why?
| Administration, Inhalation | 3 | 2022 | 661 | 0.100 |
Why?
| Wound Infection | 1 | 2013 | 29 | 0.100 |
Why?
| Neutrophil Activation | 1 | 2013 | 78 | 0.100 |
Why?
| Mycobacterium Infections | 1 | 2013 | 61 | 0.100 |
Why?
| Cellular Structures | 1 | 2011 | 4 | 0.090 |
Why?
| Comorbidity | 1 | 2016 | 1541 | 0.090 |
Why?
| Mycobacterium | 1 | 2013 | 106 | 0.090 |
Why?
| Blood Glucose Self-Monitoring | 1 | 2016 | 601 | 0.090 |
Why?
| Drug Therapy, Combination | 3 | 2021 | 1016 | 0.090 |
Why?
| Extracellular Space | 1 | 2011 | 119 | 0.090 |
Why?
| Microbial Viability | 1 | 2011 | 83 | 0.090 |
Why?
| Patient Admission | 1 | 2012 | 182 | 0.090 |
Why?
| Risk Factors | 3 | 2020 | 9737 | 0.090 |
Why?
| Infant | 1 | 2024 | 9001 | 0.090 |
Why?
| Leukocytes, Mononuclear | 1 | 2013 | 539 | 0.090 |
Why?
| Survival Rate | 2 | 2018 | 1871 | 0.080 |
Why?
| Aged | 5 | 2024 | 21976 | 0.080 |
Why?
| Blood Group Antigens | 1 | 2009 | 16 | 0.080 |
Why?
| Cardiovascular Diseases | 1 | 2021 | 2001 | 0.080 |
Why?
| Mass Screening | 1 | 2016 | 1146 | 0.080 |
Why?
| Burns | 1 | 2013 | 284 | 0.080 |
Why?
| Inflammation | 2 | 2022 | 2666 | 0.080 |
Why?
| Mucus | 1 | 2009 | 75 | 0.070 |
Why?
| Inpatients | 1 | 2012 | 468 | 0.070 |
Why?
| ADP Ribose Transferases | 1 | 2007 | 8 | 0.070 |
Why?
| Exotoxins | 1 | 2007 | 15 | 0.070 |
Why?
| Furin | 1 | 2007 | 13 | 0.070 |
Why?
| Oxygen Inhalation Therapy | 1 | 2009 | 141 | 0.070 |
Why?
| Time Factors | 3 | 2024 | 6506 | 0.070 |
Why?
| Sexual Behavior | 2 | 2022 | 482 | 0.070 |
Why?
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 17 | 0.070 |
Why?
| Cyclic GMP | 1 | 2007 | 85 | 0.070 |
Why?
| Bacterial Toxins | 1 | 2007 | 106 | 0.070 |
Why?
| Phenotype | 1 | 2015 | 3051 | 0.070 |
Why?
| Gene Expression Regulation | 1 | 2016 | 2516 | 0.070 |
Why?
| Registries | 3 | 2023 | 1883 | 0.070 |
Why?
| Sulfones | 1 | 2007 | 108 | 0.070 |
Why?
| Survivors | 1 | 2010 | 462 | 0.070 |
Why?
| Respiratory System | 1 | 2007 | 152 | 0.060 |
Why?
| Respiratory Mucosa | 1 | 2007 | 304 | 0.060 |
Why?
| Piperazines | 1 | 2007 | 333 | 0.060 |
Why?
| European Union | 1 | 2024 | 10 | 0.060 |
Why?
| Respiration, Artificial | 1 | 2009 | 604 | 0.060 |
Why?
| Logistic Models | 2 | 2019 | 1980 | 0.050 |
Why?
| Reproductive Health Services | 1 | 2023 | 16 | 0.050 |
Why?
| Standard of Care | 1 | 2024 | 72 | 0.050 |
Why?
| United States Food and Drug Administration | 1 | 2024 | 198 | 0.050 |
Why?
| Nose | 1 | 2023 | 64 | 0.050 |
Why?
| Anemia, Iron-Deficiency | 1 | 2024 | 57 | 0.050 |
Why?
| Cell Separation | 2 | 2016 | 312 | 0.050 |
Why?
| Deoxyribonuclease I | 1 | 2022 | 38 | 0.050 |
Why?
| Saline Solution, Hypertonic | 1 | 2022 | 38 | 0.050 |
Why?
| Rare Diseases | 1 | 2023 | 100 | 0.050 |
Why?
| Sex Education | 1 | 2022 | 28 | 0.050 |
Why?
| Hot Flashes | 1 | 2023 | 81 | 0.050 |
Why?
| Social Class | 1 | 2024 | 258 | 0.050 |
Why?
| Iron | 1 | 2024 | 282 | 0.050 |
Why?
| Contraceptive Agents | 1 | 2022 | 65 | 0.050 |
Why?
| Health Status Disparities | 1 | 2024 | 255 | 0.050 |
Why?
| Microbial Sensitivity Tests | 2 | 2014 | 352 | 0.050 |
Why?
| Social Determinants of Health | 1 | 2024 | 221 | 0.050 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2009 | 2064 | 0.050 |
Why?
| Biofilms | 2 | 2014 | 243 | 0.050 |
Why?
| Nutritional Status | 1 | 2023 | 326 | 0.050 |
Why?
| Preconception Care | 1 | 2021 | 40 | 0.040 |
Why?
| Genetic Counseling | 1 | 2021 | 72 | 0.040 |
Why?
| Societies, Medical | 1 | 2024 | 744 | 0.040 |
Why?
| Attitude | 1 | 2022 | 251 | 0.040 |
Why?
| Longevity | 1 | 2021 | 150 | 0.040 |
Why?
| Contraceptives, Oral, Hormonal | 1 | 2020 | 31 | 0.040 |
Why?
| Menopause | 1 | 2023 | 291 | 0.040 |
Why?
| Ambulatory Care | 1 | 2023 | 504 | 0.040 |
Why?
| Condoms | 1 | 2020 | 103 | 0.040 |
Why?
| Sequence Analysis, DNA | 1 | 2022 | 775 | 0.040 |
Why?
| Tetraspanin 30 | 1 | 2018 | 10 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2019 | 137 | 0.040 |
Why?
| British Columbia | 1 | 2018 | 14 | 0.040 |
Why?
| Sex Factors | 1 | 2024 | 1951 | 0.040 |
Why?
| Genetic Testing | 1 | 2021 | 428 | 0.040 |
Why?
| Healthcare Disparities | 1 | 2024 | 579 | 0.040 |
Why?
| Ecosystem | 1 | 2023 | 566 | 0.040 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2012 | 2433 | 0.040 |
Why?
| Case-Control Studies | 2 | 2016 | 3339 | 0.040 |
Why?
| trans-Golgi Network | 2 | 2007 | 13 | 0.040 |
Why?
| Gene Deletion | 1 | 2018 | 370 | 0.030 |
Why?
| Morbidity | 1 | 2018 | 301 | 0.030 |
Why?
| Nitric Oxide Synthase Type II | 2 | 2007 | 169 | 0.030 |
Why?
| Drug Administration Routes | 1 | 2016 | 38 | 0.030 |
Why?
| Cells, Cultured | 2 | 2018 | 4017 | 0.030 |
Why?
| Genetic Variation | 1 | 2021 | 935 | 0.030 |
Why?
| Leadership | 1 | 2020 | 352 | 0.030 |
Why?
| Interferon-alpha | 1 | 2016 | 193 | 0.030 |
Why?
| Depression | 1 | 2024 | 1292 | 0.030 |
Why?
| Practice Patterns, Physicians' | 1 | 2023 | 1262 | 0.030 |
Why?
| Colorado | 2 | 2018 | 4399 | 0.030 |
Why?
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 69 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2025 | 5045 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2016 | 856 | 0.030 |
Why?
| Rats | 1 | 2022 | 5246 | 0.030 |
Why?
| Medication Adherence | 1 | 2018 | 558 | 0.030 |
Why?
| Odds Ratio | 1 | 2016 | 1019 | 0.030 |
Why?
| Cohort Studies | 1 | 2023 | 5402 | 0.030 |
Why?
| Survival Analysis | 1 | 2016 | 1265 | 0.030 |
Why?
| Ciprofloxacin | 1 | 2013 | 30 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2016 | 1499 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 324 | 0.020 |
Why?
| Superoxides | 1 | 2013 | 198 | 0.020 |
Why?
| Drug Synergism | 1 | 2013 | 357 | 0.020 |
Why?
| Cell Line | 2 | 2007 | 2741 | 0.020 |
Why?
| Suspensions | 1 | 2011 | 36 | 0.020 |
Why?
| Enteral Nutrition | 1 | 2012 | 186 | 0.020 |
Why?
| Cell Adhesion | 1 | 2011 | 445 | 0.020 |
Why?
| Age Distribution | 1 | 2010 | 373 | 0.020 |
Why?
| Sex Distribution | 1 | 2010 | 358 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2021 | 7057 | 0.020 |
Why?
| Insulin Infusion Systems | 1 | 2012 | 362 | 0.020 |
Why?
| Age of Onset | 1 | 2010 | 495 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2013 | 1938 | 0.020 |
Why?
| Feedback, Physiological | 1 | 2007 | 76 | 0.020 |
Why?
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 21 | 0.020 |
Why?
| Epithelial Sodium Channels | 1 | 2007 | 18 | 0.020 |
Why?
| Guanylate Cyclase | 1 | 2007 | 33 | 0.020 |
Why?
| Sodium | 1 | 2007 | 202 | 0.020 |
Why?
| Purines | 1 | 2007 | 169 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 2007 | 541 | 0.020 |
Why?
| In Vitro Techniques | 1 | 2007 | 1047 | 0.020 |
Why?
| Transforming Growth Factor beta | 1 | 2007 | 443 | 0.010 |
Why?
| Patient Acceptance of Health Care | 1 | 2010 | 757 | 0.010 |
Why?
| Hypoglycemic Agents | 1 | 2012 | 1217 | 0.010 |
Why?
| Mice | 2 | 2013 | 16620 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2013 | 3947 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2007 | 2069 | 0.010 |
Why?
| Nitric Oxide | 1 | 2007 | 881 | 0.010 |
Why?
| Insulin | 1 | 2012 | 2316 | 0.010 |
Why?
| Macrophages | 1 | 2007 | 1464 | 0.010 |
Why?
| Signal Transduction | 1 | 2007 | 4825 | 0.010 |
Why?
|
|
Taylor-Cousar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|